Join the Skyrizi group to help and get support from people like you.
Skyrizi News
Risankizumab Noninferior, Superior to Ustekinumab for Crohn Disease
WEDNESDAY, July 17, 2024 – For patients with moderate-to-severe Crohn disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for endoscopic remission...
FDA Approves Skyrizi (risankizumab-rzaa) for Ulcerative Colitis
NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Skyrizi® (risankizumab-rzaa) for adults with moderately ...
Skyrizi (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Third approved indication for Skyrizi (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating Skyrizi in moderately to severely...
FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
NORTH CHICAGO, Ill., April 23, 2019 /PRNewswire/ – AbbVie today announced that the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Crohn's Disease, Psoriatic Arthritis, Plaque Psoriasis, Psoriasis, Ulcerative Colitis